Co-injection of anti-HER2 antibody Trastuzumab does not increase efficacy of [¹⁷⁷Lu]Lu-PSMA-617 therapy in an animal model of prostate cancer.

ABSTRACT: One novel option for treating metastatic castration resistant prostate cancer is radionuclide therapy targeting prostate-specific membrane antigen (PSMA), e.g. [¹⁷⁷Lu]Lu-PSMA-617. Overexpression of HER2 has been found in 80% of metastatic cases of prostate cancer. Previous research showed that HER2 is elevated post irradiation in PC-3 prostate cancer cells. Co-treating with anti-HER2 antibody Trastuzumab gave less proliferation of irradiated tumor cells in vitro, and when using radionuclide therapy, also in vivo. The aim of this study is to determine whether the same holds true in PSMA-expressing PC-3 PIP cells using [¹⁷⁷Lu]Lu-PSMA-617 radionuclide therapy. PC-3 PIP and 22Rv1 prostate cancer cells were tested in vitro, treated with 6 Gy of x-rays with or without Trast

SUBMITTER: Abouzayed A 

PROVIDER: S-EPMC10349288 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature